Chemical Compound Review:
refecoxib 4-(4-methylsulfonylphenyl)-3- phenyl-5H...
Synonyms:
rofecoxib, Ceoxx, Vioxx, CHEMBL122, SureCN3050, ...
Kevin Horgan,
Simon,
Guglielmi,
Kruklitis,
Robert Ridell,
Lipetz,
Antonio Rossi,
Patrignani,
Paolo Maione,
Hinz,
Arbogast,
Douglas Watson,
Massimo Di Maio,
Marianna Alacqua,
Gianluca Trifirò,
Lorenzo Cavagna,
Roberto Caporali,
Carlo Maurizio Montecucco,
Salvatore Moretti,
Domenico Ugo Tari,
Mariella Galdo,
Achille P. Caputi,
Vincenzo Arcoraci,
John A. Baron,
Holzapfel,
Francesco Carozza,
Brune,
Riddell,
Griffin,
Bolognese,
Capone,
Stern,
Rassen,
Moretta,
Francesco Rosetti,
Baron,
Robert S. Sandler,
Schnitzer,
Alessandro Morabito,
Kvien,
Kapoor,
Thal,
Domenico Galetta,
Bettina Oxenius,
Tanaka,
Bath,
Young,
Lutz,
Hui Quan,
Ouyang,
Bolognese,
Santi Barbera,
Cano,
Kivitz,
Stein,
Henry,
Antonio Testa,
Hawkey,
Cesare Gridelli,
Brookhart,
Kaiser,
Beck,
Dion Morton,
Teresa Gamucci,
Quan,
Hall,
Vittorio Gebbia,
Quan,
Francesco Perrone,
Solomon,
Baccante,
Shapiro,
Collantes-Estevez,
Davis,
Jim Bolognese,
Ciro Gallo,
Sano,
Fraek,
Francesco Cognetti,
Antonucci,
Fortunato Ciardiello,
Adolfo Favaretto,
Sandler,
Di Febbo,
Sterman,
Farlow,
Schwartz,
Johanson,
Whissell,
Morton,
Harper,
Yaron Niv,
Bruno Daniele,
Laine,
Sciulli,
Hochberg,
Sanders,
Neuhofer,
Bresalier,
Angel Lanas,
Ricciotti,
Bombardier,
Robert Bresalier,
Anna Ceribelli,
Day,
Hee,
Germond,
Schneeweiss,
Oxenius,
Schnitzer,
Aisen,
Laine,
Horgan,
Schafer,
Dormann,
Lopez,
Reicin,
Loftus,
Tomas J. Cook,
Susan Loftus,
Wang,
Davis,
Noble,
Ferraz,
DeLong,
Jin,
Grundman,
Robert Schoen,
Pfeiffer,
Albelda,
Tacconelli,
Carol Burke,
Ray,
Porreca,
Fernandez-Perez,
Lanas,
Burgos-Vargas,
Thomas,
Stuppia,
Daugherty,
- Upper gastrointestinal toxicity of rofecoxib and naproxen. Gupta, S. N. Engl. J. Med. (2001)
- Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. Bombardier, C., Laine, L., Reicin, A., Shapiro, D., Burgos-Vargas, R., Davis, B., Day, R., Ferraz, M.B., Hawkey, C.J., Hochberg, M.C., Kvien, T.K., Schnitzer, T.J. N. Engl. J. Med. (2000)
- Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs. Langman, M.J., Jensen, D.M., Watson, D.J., Harper, S.E., Zhao, P.L., Quan, H., Bolognese, J.A., Simon, T.J. JAMA (1999)
- Using cyclooxygenase-2 inhibitors as molecular platforms to develop a new class of apoptosis-inducing agents. Zhu, J., Song, X., Lin, H.P., Young, D.C., Yan, S., Marquez, V.E., Chen, C.S. J. Natl. Cancer Inst. (2002)
- Is the demonstration of adenoma reduction with rofecoxib a pyrrhic victory? Lynch, P.M. Gastroenterology (2006)
- Peptic ulcer and bleeding events associated with rofecoxib in a 3-year colorectal adenoma chemoprevention trial. Lanas, A., Baron, J.A., Sandler, R.S., Horgan, K., Bolognese, J., Oxenius, B., Quan, H., Watson, D., Cook, T.J., Schoen, R., Burke, C., Loftus, S., Niv, Y., Ridell, R., Morton, D., Bresalier, R. Gastroenterology (2007)
- Changes in the characteristics of patients prescribed selective cyclooxygenase 2 inhibitors after the 2004 withdrawal of rofecoxib. Setakis, E., Leufkens, H.G., van Staa, T.P. Arthritis Rheum. (2008)
- Chronic COX-2 inhibition reduces medullary HSP70 expression and induces papillary apoptosis in dehydrated rats. Neuhofer, W., Holzapfel, K., Fraek, M.L., Ouyang, N., Lutz, J., Beck, F.X. Kidney Int. (2004)
- Anti-inflammatory treatment with acetylsalicylate or rofecoxib is not neuroprotective in Huntington's disease transgenic mice. Norflus, F., Nanje, A., Gutekunst, C.A., Shi, G., Cohen, J., Bejarano, M., Fox, J., Ferrante, R.J., Hersch, S.M. Neurobiol. Dis. (2004)
- The selective cyclooxygenase-2 inhibitor rofecoxib suppresses brain inflammation and protects cholinergic neurons from excitotoxic degeneration in vivo. Scali, C., Giovannini, M.G., Prosperi, C., Bellucci, A., Pepeu, G., Casamenti, F. Neuroscience (2003)
- Psychotropic effects of COX-2 inhibitors--a possible new approach for the treatment of psychiatric disorders. Müller, N., Riedel, M., Schwarz, M.J. Pharmacopsychiatry (2004)
- Improved control of osteoarthritis pain and self-reported health status in non-responders to celecoxib switched to rofecoxib: results of PAVIA, an open-label post-marketing survey in Spain. Collantes-Estevez, E., Fernandez-Perez, C. Current medical research and opinion. (2003)
- Upper gastrointestinal toxicity of rofecoxib and naproxen. Delgado Fernández, M., Zambrana García, J.L., Diez García, F. N. Engl. J. Med. (2001)
- Inhibition of angiogenesis by nonsteroidal anti-inflammatory drugs: insight into mechanisms and implications for cancer growth and ulcer healing. Jones, M.K., Wang, H., Peskar, B.M., Levin, E., Itani, R.M., Sarfeh, I.J., Tarnawski, A.S. Nat. Med. (1999)
- Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. Aisen, P.S., Schafer, K.A., Grundman, M., Pfeiffer, E., Sano, M., Davis, K.L., Farlow, M.R., Jin, S., Thomas, R.G., Thal, L.J. JAMA (2003)
- A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis.Rofecoxib Osteoarthritis Endoscopy Study Group. Laine, L., Harper, S., Simon, T., Bath, R., Johanson, J., Schwartz, H., Stern, S., Quan, H., Bolognese, J. Gastroenterology (1999)
- Rofecoxib inhibits cyclooxygenase 2 expression and activity and reduces cell proliferation in Barrett's esophagus. Kaur, B.S., Khamnehei, N., Iravani, M., Namburu, S.S., Lin, O., Triadafilopoulos, G. Gastroenterology (2002)
- Chemoprevention of intestinal polyposis in the Apcdelta716 mouse by rofecoxib, a specific cyclooxygenase-2 inhibitor. Oshima, M., Murai, N., Kargman, S., Arguello, M., Luk, P., Kwong, E., Taketo, M.M., Evans, J.F. Cancer Res. (2001)
- Rofecoxib, a specific inhibitor of cyclooxygenase 2, with clinical efficacy comparable with that of diclofenac sodium: results of a one-year, randomized, clinical trial in patients with osteoarthritis of the knee and hip. Rofecoxib Phase III Protocol 035 Study Group. Cannon, G.W., Caldwell, J.R., Holt, P., McLean, B., Seidenberg, B., Bolognese, J., Ehrich, E., Mukhopadhyay, S., Daniels, B. Arthritis Rheum. (2000)
- Phase II clinical trial results involving treatment with low-dose daily oral cyclophosphamide, weekly vinblastine, and rofecoxib in patients with advanced solid tumors. Young, S.D., Whissell, M., Noble, J.C., Cano, P.O., Lopez, P.G., Germond, C.J. Clin. Cancer Res. (2006)
- Acute tubulointerstitial nephritis associated with the selective COX-2 enzyme inhibitor, rofecoxib. Rocha, J.L., Fernández-Alonso, J. Lancet (2001)
- Celecoxib-induced apoptosis in rat cholangiocarcinoma cells mediated by Akt inactivation and Bax translocation. Zhang, Z., Lai, G.H., Sirica, A.E. Hepatology (2004)
- More pronounced inhibition of cyclooxygenase 2, increase in blood pressure, and reduction of heart rate by treatment with diclofenac compared with celecoxib and rofecoxib. Hinz, B., Dormann, H., Brune, K. Arthritis Rheum. (2006)
- A selective COX-2 inhibitor suppresses chronic pancreatitis in an animal model (WBN/Kob rats): significant reduction of macrophage infiltration and fibrosis. Reding, T., Bimmler, D., Perren, A., Sun, L.K., Fortunato, F., Storni, F., Graf, R. Gut (2006)
- Central retinal vein occlusion in a patient with rheumatoid arthritis taking rofecoxib. Meyer, C., Gähler, R. Lancet (2002)
- The effect of the selective cyclooxygenase-2 inhibitor rofecoxib on human colorectal cancer liver metastases. Fenwick, S.W., Toogood, G.J., Lodge, J.P., Hull, M.A. Gastroenterology (2003)
- Celecoxib exhibits the greatest potency amongst cyclooxygenase (COX) inhibitors for growth inhibition of COX-2-negative hematopoietic and epithelial cell lines. Waskewich, C., Blumenthal, R.D., Li, H., Stein, R., Goldenberg, D.M., Burton, J. Cancer Res. (2002)
- Rofecoxib, a COX-2 inhibitor, does not inhibit human gastric mucosal prostaglandin production. Wight, N.J., Gottesdiener, K., Garlick, N.M., Atherton, C.T., Novak, S., Gertz, B.J., Calder, N.A., Cote, J., Wong, P., Dallob, A., Hawkey, C.J. Gastroenterology (2001)
- Reduced thromboxane biosynthesis in carriers of toll-like receptor 4 polymorphisms in vivo. Patrignani, P., Di Febbo, C., Tacconelli, S., Moretta, V., Baccante, G., Sciulli, M.G., Ricciotti, E., Capone, M.L., Antonucci, I., Guglielmi, M.D., Stuppia, L., Porreca, E. Blood (2006)
- Simultaneous assessment of short-term gastrointestinal benefits and cardiovascular risks of selective cyclooxygenase 2 inhibitors and nonselective nonsteroidal antiinflammatory drugs: an instrumental variable analysis. Schneeweiss, S., Solomon, D.H., Wang, P.S., Rassen, J., Brookhart, M.A. Arthritis Rheum. (2006)
- A randomized trial measuring fecal blood loss after treatment with rofecoxib, ibuprofen, or placebo in healthy subjects. Hunt, R.H., Bowen, B., Mortensen, E.R., Simon, T.J., James, C., Cagliola, A., Quan, H., Bolognese, J.A. Am. J. Med. (2000)
- Factorial phase III randomised trial of rofecoxib and prolonged constant infusion of gemcitabine in advanced non-small-cell lung cancer: the GEmcitabine-COxib in NSCLC (GECO) study. Gridelli, C., Gallo, C., Ceribelli, A., Gebbia, V., Gamucci, T., Ciardiello, F., Carozza, F., Favaretto, A., Daniele, B., Galetta, D., Barbera, S., Rosetti, F., Rossi, A., Maione, P., Cognetti, F., Testa, A., Di Maio, M., Morabito, A., Perrone, F. Lancet Oncol. (2007)
- Prescribing pattern of drugs in the treatment of osteoarthritis in Italian general practice: the effect of rofecoxib withdrawal. Alacqua, M., Trifirò, G., Cavagna, L., Caporali, R., Montecucco, C.M., Moretti, S., Tari, D.U., Galdo, M., Caputi, A.P., Arcoraci, V. Arthritis Rheum. (2008)
- Inhibition of cyclooxygenase-2 by rofecoxib attenuates the growth and metastatic potential of colorectal carcinoma in mice. Yao, M., Kargman, S., Lam, E.C., Kelly, C.R., Zheng, Y., Luk, P., Kwong, E., Evans, J.F., Wolfe, M.M. Cancer Res. (2003)
- Prostaglandin E2 enhances pancreatic cancer invasiveness through an Ets-1-dependent induction of matrix metalloproteinase-2. Ito, H., Duxbury, M., Benoit, E., Clancy, T.E., Zinner, M.J., Ashley, S.W., Whang, E.E. Cancer Res. (2004)
- A randomized trial of rofecoxib for the chemoprevention of colorectal adenomas. Baron, J.A., Sandler, R.S., Bresalier, R.S., Quan, H., Riddell, R., Lanas, A., Bolognese, J.A., Oxenius, B., Horgan, K., Loftus, S., Morton, D.G. Gastroenterology (2006)
- COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease. Ray, W.A., Stein, C.M., Daugherty, J.R., Hall, K., Arbogast, P.G., Griffin, M.R. Lancet (2002)
- Use of cyclooxygenase-2 inhibition to enhance the efficacy of immunotherapy. DeLong, P., Tanaka, T., Kruklitis, R., Henry, A.C., Kapoor, V., Kaiser, L.R., Sterman, D.H., Albelda, S.M. Cancer Res. (2003)
- Comparison of the COX-inhibiting nitric oxide donator AZD3582 and rofecoxib in treating the signs and symptoms of Osteoarthritis of the knee. Schnitzer, T.J., Kivitz, A.J., Lipetz, R.S., Sanders, N., Hee, A. Arthritis Rheum. (2005)